Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II ZR-MTX trial for primary intraocular lymphoma
ChiCTR2500104446Phase 2Recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Jun 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab, zanubrutinib and methotrexate in primary intraocular lymphoma (PIOL), sponsored by Peking Union Medical College Hospital. Primary endpoint: Progression-free survival. Started Jun 2025; status: recruiting.
02
Drugs
rituximabzanubrutinibmethotrexate
03
Conditions
primary intraocular lymphoma (PIOL)
Beyond the preview
Go deeper on ChiCTR2500104446.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500104446.